Cargando…

The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever

BACKGROUND: Dengue fever is a mosquito-borne virus belonging to the family Flaviviridae. It is an old virus that has re-emerged globally over the past 20 years and now causes a global burden of 50 million infections per year across approximately 100 countries. Despite this, there is no safe vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Soroy, Lardo, Bagus, Sulistyo, Yongkie, Iswandi Purnama, Djoko, Wibisono
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266269/
https://www.ncbi.nlm.nih.gov/pubmed/25525372
http://dx.doi.org/10.2147/IDR.S71505
_version_ 1782349002694459392
author Soroy, Lardo
Bagus, Sulistyo
Yongkie, Iswandi Purnama
Djoko, Wibisono
author_facet Soroy, Lardo
Bagus, Sulistyo
Yongkie, Iswandi Purnama
Djoko, Wibisono
author_sort Soroy, Lardo
collection PubMed
description BACKGROUND: Dengue fever is a mosquito-borne virus belonging to the family Flaviviridae. It is an old virus that has re-emerged globally over the past 20 years and now causes a global burden of 50 million infections per year across approximately 100 countries. Despite this, there is no safe vaccine available, and therapy is largely supportive. Its pathogenesis is multifaceted and currently still poorly understood, leading to a lack of disease-specific therapy. Propolis is a natural antiviral and anti-inflammatory product derived from the saps of plants and mixed with the saliva of honeybees. Propoelix™ is a uniquely potent and water-soluble extract of propolis containing high concentrations of anti-inflammatory compounds like caffeic acid phenethyl ester. OBJECTIVE: The primary objective is to determine the effectiveness of a unique propolis extract (Propoelix™) on the clinical course of patients with dengue hemorrhagic fever (DHF). The secondary objective is to examine the effect of Propoelix™ on tumor necrosis factor-α (TNF-α) levels in patients with DHF. METHODS: A double-blind, randomized, placebo-controlled trial was conducted at the Department of Internal Medicine, Gatot Soebroto Central Army Hospital in Jakarta, Indonesia, from May 2012 to July 2013. Sixty-three patients who met the inclusion criteria were enrolled in the trial. Patients were randomized to receive either two capsules of Propoelix™ 200 mg three times a day or placebo daily for 7 days. Clinical and laboratory variables of both groups, including the anti-inflammatory marker TNF-α, were investigated. Patients were deemed technically fit for discharge if their platelet counts had recovered and exceeded 100,000/μL but were all observed as inpatients for 7 days. RESULTS: There were 31 patients in the Propoelix™ treatment group and 32 patients in the placebo group. Platelet counts in the Propoelix™-treated group showed a trend toward a faster recovery by day 3 of admission and became statistically significant by day 6 (101.42±48.79 vs 80.78±43.35 [10(3)/mL], P=0.042) and day 7 (146.67±64.68 vs 107.84±57.22 [10(3)/mL], P=0.006). Patients treated with Propoelix™ had a significantly greater decline in TNF-α levels on day 7 of therapy compared with patients in the placebo group (P=0.018). They also had a significantly shorter length of hospitalization compared with those in the placebo group (4.69±0.78 days vs 5.46±1.16 days, P=0.012). CONCLUSION: Propoelix™ appears to hasten the improvement in platelet counts and TNF-α levels and shortens the duration of hospitalization in patients with DHF.
format Online
Article
Text
id pubmed-4266269
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42662692014-12-18 The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever Soroy, Lardo Bagus, Sulistyo Yongkie, Iswandi Purnama Djoko, Wibisono Infect Drug Resist Original Research BACKGROUND: Dengue fever is a mosquito-borne virus belonging to the family Flaviviridae. It is an old virus that has re-emerged globally over the past 20 years and now causes a global burden of 50 million infections per year across approximately 100 countries. Despite this, there is no safe vaccine available, and therapy is largely supportive. Its pathogenesis is multifaceted and currently still poorly understood, leading to a lack of disease-specific therapy. Propolis is a natural antiviral and anti-inflammatory product derived from the saps of plants and mixed with the saliva of honeybees. Propoelix™ is a uniquely potent and water-soluble extract of propolis containing high concentrations of anti-inflammatory compounds like caffeic acid phenethyl ester. OBJECTIVE: The primary objective is to determine the effectiveness of a unique propolis extract (Propoelix™) on the clinical course of patients with dengue hemorrhagic fever (DHF). The secondary objective is to examine the effect of Propoelix™ on tumor necrosis factor-α (TNF-α) levels in patients with DHF. METHODS: A double-blind, randomized, placebo-controlled trial was conducted at the Department of Internal Medicine, Gatot Soebroto Central Army Hospital in Jakarta, Indonesia, from May 2012 to July 2013. Sixty-three patients who met the inclusion criteria were enrolled in the trial. Patients were randomized to receive either two capsules of Propoelix™ 200 mg three times a day or placebo daily for 7 days. Clinical and laboratory variables of both groups, including the anti-inflammatory marker TNF-α, were investigated. Patients were deemed technically fit for discharge if their platelet counts had recovered and exceeded 100,000/μL but were all observed as inpatients for 7 days. RESULTS: There were 31 patients in the Propoelix™ treatment group and 32 patients in the placebo group. Platelet counts in the Propoelix™-treated group showed a trend toward a faster recovery by day 3 of admission and became statistically significant by day 6 (101.42±48.79 vs 80.78±43.35 [10(3)/mL], P=0.042) and day 7 (146.67±64.68 vs 107.84±57.22 [10(3)/mL], P=0.006). Patients treated with Propoelix™ had a significantly greater decline in TNF-α levels on day 7 of therapy compared with patients in the placebo group (P=0.018). They also had a significantly shorter length of hospitalization compared with those in the placebo group (4.69±0.78 days vs 5.46±1.16 days, P=0.012). CONCLUSION: Propoelix™ appears to hasten the improvement in platelet counts and TNF-α levels and shortens the duration of hospitalization in patients with DHF. Dove Medical Press 2014-12-09 /pmc/articles/PMC4266269/ /pubmed/25525372 http://dx.doi.org/10.2147/IDR.S71505 Text en © Soroy et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Soroy, Lardo
Bagus, Sulistyo
Yongkie, Iswandi Purnama
Djoko, Wibisono
The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever
title The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever
title_full The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever
title_fullStr The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever
title_full_unstemmed The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever
title_short The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever
title_sort effect of a unique propolis compound (propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266269/
https://www.ncbi.nlm.nih.gov/pubmed/25525372
http://dx.doi.org/10.2147/IDR.S71505
work_keys_str_mv AT soroylardo theeffectofauniquepropoliscompoundpropoelixonclinicaloutcomesinpatientswithdenguehemorrhagicfever
AT bagussulistyo theeffectofauniquepropoliscompoundpropoelixonclinicaloutcomesinpatientswithdenguehemorrhagicfever
AT yongkieiswandipurnama theeffectofauniquepropoliscompoundpropoelixonclinicaloutcomesinpatientswithdenguehemorrhagicfever
AT djokowibisono theeffectofauniquepropoliscompoundpropoelixonclinicaloutcomesinpatientswithdenguehemorrhagicfever
AT soroylardo effectofauniquepropoliscompoundpropoelixonclinicaloutcomesinpatientswithdenguehemorrhagicfever
AT bagussulistyo effectofauniquepropoliscompoundpropoelixonclinicaloutcomesinpatientswithdenguehemorrhagicfever
AT yongkieiswandipurnama effectofauniquepropoliscompoundpropoelixonclinicaloutcomesinpatientswithdenguehemorrhagicfever
AT djokowibisono effectofauniquepropoliscompoundpropoelixonclinicaloutcomesinpatientswithdenguehemorrhagicfever